等待开盘 08-25 09:30:00 美东时间
-0.490
-0.75%
今日重点评级关注:HC Wainwright & Co.:维持Innate Pharma"买入"评级,目标价从5美元升至7美元;HC Wainwright & Co.:维持Immix Biopharma"买入"评级,目标价从20美元升至25美元
08-11 11:45
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $62 to $70.
08-07 07:08
今日重点评级关注:HC Wainwright & Co.:维持Precigen"买入"评级,目标价从14美元升至18美元;HC Wainwright & Co.:维持Sophia Genetics"买入"评级,目标价从12美元升至14美元
08-06 11:36
Travere Therapeutics Inc. (NASDAQ:TVTX) shares surged 13.44% to $63.55 in after-hours trading on Tuesday after the biopharmaceutical company posted second-quarter revenue that beat analyst expectations, even as earnings missed. Revenue Beat Drives Momentum For the period ended Jun. 30, Travere repor...
08-05 15:16
华盛资讯8月5日讯,Travere Therapeutics, Inc.公布2026财年Q2业绩,公司Q2营收1.70亿美元,同比增长48.2%,归母净利润亏损0.35亿美元,同比亏损扩大172.8%。
08-05 04:28
今日重点评级关注:HC Wainwright & Co.:维持TOMI Environmental Solutions"买入"评级,目标价从3.5美元升至7美元;Canaccord Genuity:维持Viking Therapeutics"买入"评级,目标价从107美元升至114美元
07-31 11:43
Canaccord Genuity analyst Edward Nash maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $56 to $62.
07-30 23:55
云顶新耀(01952.HK)发布公告,有关与Travere Therapeutics, Inc.签订独家许可与合作协议。交割已根据该协议的条款进行。
07-07 17:40
今日重点评级关注:Chardan Capital:维持Ocular Therapeutix"买入"评级,目标价从21美元升至23美元;Guggenheim:维持Amylyx Pharmaceuticals"买入"评级,目标价从30美元升至40美元
06-26 17:42